Trial · NCT06674577
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
NCT06674577, Phase 2, Enrolling by invitation, Vera Therapeutics, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept. Trials, record NCT06674577. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06674577
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
- NCT number
- NCT06674577
- Status
- Enrolling by invitation
- Phases
- Phase 2
- Enrollment
- 750 participants, estimated
- Lead sponsor
- Vera Therapeutics, Inc.
- Conditions
- IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
- Interventions
- Atacicept 150 mg
- First posted
- 2024-11-05
- Last updated
- 2026-06-22
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of adverse events observed during the dosing period | Baseline until end of study up to week156 | Patient incidence of reported Adverse Events (AEs) |
| Secondary | To evaluate the effect of atacicept on change in proteinuria | Baseline until end of study up to week156 | Changes in proteinuria based on UPCR (Urine Protein Creatinine Ratio) and UACR (Urine Albumin-Creatinine Ratio) on spot urine. |
| Secondary | To evaluate the effect of atacicept on the change in estimated glomerular filtration rate (eGFR) using serum creatinine and cystatin C, respectively | Baseline until end of study up to week156 | Changes in estimated glomerular filtration rate (eGFR) based on serum creatinine and cystatain C, respectively |
| Secondary | To evaluate the effect of atacicept on hematuria | Baseline until end of study up to week156 | Hematuria level based on blood on urine dipstick |
| Secondary | To evaluate the effect of atacicept on serum galactose-deficient IgA1 (Gd-IgA1) levels | Baseline until end of study up to week156 | Changes in serum Gd-IgA1 levels |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06674577
GET https://conductscience.org/api/trials/v1/NCT06674577/registered